Drug Profile
Rezafungin acetate - Cidara Therapeutics
Alternative Names: Biafungin; CD 101; CD 101 IV; CD 101 Topical; Rezafungin; Rezafungin acetate; REZZAYO; Rezzayo; SP-3025Latest Information Update: 02 Feb 2024
Price :
$50
*
At a glance
- Originator Seachaid Pharmaceuticals
- Developer Cidara Therapeutics; Mundipharma International
- Class Acetates; Amides; Antifungals; Aza compounds; Echinocandins; Phenols; Phenyl ethers; Small molecules
- Mechanism of Action Glucan synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Candidaemia; Invasive candidiasis
- Phase III Mycoses
- Phase II Pneumocystis pneumonia
- Discontinued Aspergillosis; Vulvovaginal candidiasis